kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human PD-L1/B7-H1 Protein, low endotoxin, Fc Tag, 100µg  

Recombinant Human PD-L1/B7-H1 Protein, low endotoxin, Fc Tag, 100µg

Recombinant Human PD-L1 /B7-H1 /CD274 Protein, Phe 19 - Arg 238, produced in human 293 cells (HEK293), low endotoxin, Fc Tag (MALS verified)

Recombinant Human Protein, PD-L1, CD274, B7-H1, PDCD1L1, PDCD1LG1

More details


Availability: within 7 days

416,00 €

Programmed cell death 1 ligand 1 (PDL1) is also known as B7-H, B7H1, MGC142294, MGC142296, PD-L1, PDCD1L1 and PDCD1LG1,which is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses.PDL1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. This protein is broadly expressed in the majority of peripheral tissues as well as hematopoietic cells. Interaction between PDL1 and its receptors belonging to the CD28 family of molecules provide both stimulatory and inhibitory signals in regulating T cell activation and tolerance. PDL1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression.

Recombinant Human PD-L1, Fc Tag (PD1-H5258) is expressed from human 293 cells (HEK293). It contains AA Phe 19 - Arg 238 (Accession # NP_054862.1).
Predicted N-terminus: Phe 19

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 51.3 kDa. The protein migrates as 60-75 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Less than 0.1 EU per μg by the LAL method.

>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 24 months in lyophilized state;
-70°C for 12 months under sterile conditions after reconstitution.

Please refer to product data sheet.

Clinical and Translational Updates

(1) "The prognostic value of tumour-infiltrating lymphocytes, programmed cell death protein-1 and programmed cell death ligand-1 in Stage I-III triple-negative breast cancer"
Sun, Zhang, Wang et al
Br J Cancer (2023)
(2) "Differences in the immune microenvironment between improved and non-improved cases of vitiligo after halo nevus excision"
Kano, Nakamura, Nojiri et al
J Dermatol Sci (2023)
(3) "A Cascade-Targeted Enzyme-Instructed Peptide Self-Assembly Strategy for Cancer Immunotherapy through Boosting Immunogenic Cell Death"
Xie, Ding, Zhang et al
Small Methods (2023)
Showing 1-3 of 24307papers.


(1) "Novel anti-PD-1 antibodies"
Authors: X Qian, et al
Journal: US20190330348A1 2019
Application: immunization & ELISA
(2) "Comprehensive in vitro characterization of PD-L1 small molecule inhibitors"
Authors: Ganesan A, et al
Journal: Sci Rep 2019
Application: SPR
(3) "Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction"
Authors: Boohaker RJ, et al.
Journal: Cancer Lett 2018
Application: BLI
(4) "Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies"
Authors: Yam Alice, et al.
Journal: US20180142022A1 2018
Application: ELISA